European journal of rheumatology最新文献

{"title":"Anti IL-6 Treatment for Calcium Pyrophosphate Disease Report of 4 Cases and a Short Literature Review.","authors":"Amir Bieber, Angelo Tropea, Shay Brikman, Antonino Palumbo, Fabiola Atzeni","doi":"10.5152/eurjrheum.2026.25080","DOIUrl":"10.5152/eurjrheum.2026.25080","url":null,"abstract":"<p><p>Calcium pyrophosphate deposition disease (CPPD) is a prevalent cause of inflammatory arthritis in older adults, often complicated by comorbidities that limit standard anti-inflammatory therapies. Despite its burden, evidence for biologic treatments remains limited. Four patients with CPPD, 3 with chronic polyarthritis, and 1 with overlapping gout are presented. All patients were treated with tocilizumab (TCZ) after failure or intolerance to colchicine, non-steroidal anti-inflammatory drugs, or corticosteroids. All patients experienced partial clinical improvement, with reduced inflammation markers and modest reductions in flare frequency or severity. However, corticosteroid dependence persisted in most cases, and the improvement assessment was mostly subjective. Tocilizumab was well tolerated without serious adverse events. Recent reports suggest a potential role for IL-6 blockade in CPPD, yet efficacy remains variable. Comparative studies with Interleukin (IL)-1 inhibitors and emerging data from observational cohorts and pilot trials support further investigation. In conclusion, TCZ may offer clinical benefit in refractory CPPD, while there is a true need for validation in controlled prospective studies. Cite this article as: Bieber A, Tropea A, Brikman S, Palumbo A, Atzeni F. Anti IL-6 treatment for calcium pyrophosphate disease report of 4 cases and a short literature review. Eur J Rheumatol. 2026, 13, 0080, doi: 10.5152/ eurjrheum.2026.25080.</p>","PeriodicalId":12066,"journal":{"name":"European journal of rheumatology","volume":"13 1","pages":"1-5"},"PeriodicalIF":1.8,"publicationDate":"2026-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13083766/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147812785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unmasking Eosinophilic Granulomatosis with Polyangiitis: A Case of Rapid-Onset Myositis Following COVID-19 Booster in an Eosinophilic Asthma Patient.","authors":"Anisha Memdani, Vishal Busa, Samhitha Avula, Alexis Ford, Joseph Nesheiwat","doi":"10.5152/eurjrheum.2026.25016","DOIUrl":"10.5152/eurjrheum.2026.25016","url":null,"abstract":"<p><p>Eosinophilic Granulomatosis with Polyangiitis (EGPA) is a rare Anti-neutrophil cytoplasm antibodies (ANCA)-associated vasculitis with multi-organ involvement and eosinophilia. We present a 61-year-old male with a history of eosinophilic asthma who developed progressive weakness and muscle aches six weeks after his second COVID-19 booster. Four to six weeks post vaccination, he developed myal gias and weakness, especially in proximal muscles, leading to a severe decline in function. Lab results showed leukocytosis (29.54 cells/mm³); 54% eosinophils; and elevated erythrocyte sedimentation rate (ESR), C-reactive protein, and creatine kinase levels at 13 736 u/L. Anti-myeloperoxidase antibodies were positive, while PR-3, C-ANCA, and P-ANCA were negative. Magnetic resonance imaging of the lower extremities showed intramuscular edema. Muscle biopsies confirmed EGPA. Diagnosed per American College of Rheumatology (ACR)/ European Alliance of Associations for Rheumatology (EULAR) criteria, he received pulse dose IV methylprednisolone with significant improvement. He was discharged on 60 mg prednisone and started on mepolizumab (300 mg subcutaneous once every 4 weeks). Eosinophilic granulomatosis with polyangiitis progresses through stages: asthma, eosinophilia with organ involvement, and vasculitis. This case highlights a unique presentation of rapid myositis without significant involvement of any other organs and vasculitis post-mRNA vaccination. While environmental factors may trigger EGPA, the role of COVID-19 vaccines remains hypothesis-generating. This case underscores the importance of post-market surveillance for rare events, contributing to the understanding of vaccine-related rheumatic disease triggers Cite this article as: Memdani A, Busa V, Avula S, Ford A, Nesheiwat J. Unmasking Eosinophilic granulomatosis with polyangiitis: a case of rapid-onset myositis following COVID-19 booster in an eosinophilic asthma patient. Eur J Rheumatol. 2025, 13(1), 0016, doi:10.5152/eurjrheum.2026.25016.</p>","PeriodicalId":12066,"journal":{"name":"European journal of rheumatology","volume":"13 1","pages":"1-5"},"PeriodicalIF":1.8,"publicationDate":"2026-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13083772/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147812801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Eosinophilic Granulomatous Polyangiitis Emerging After Omalizumab Administration: An Asthma Patient Without Systemic Corticosteroids Develops Mononeuritis Multiplex After 22 Days.","authors":"Zhuo Wang, Shuaiyu Lin, Jiong Yang, Ming Cheng, Mu Cai","doi":"10.5152/eurjrheum.2026.25048","DOIUrl":"10.5152/eurjrheum.2026.25048","url":null,"abstract":"<p><p>Omalizumab is an anti-immunoglobulin E (IgE) monoclonal antibody used to treat severe allergic asthma. Although most of the reported cases of omalizumab-associated eosinophilic granulomatous polyangiitis (EGPA) are attributed to the accompanying glucocorticoid reduction, a patient who met the 2022 American College of Rheumatology diagnostic criteria for EGPA yet had no history of systemic glucocorticoid treatment is described. This individual developed limb numbness accompanied by eosinophilia (14.24 × 109/L) within 22 days after initiating omalizumab therapy. Critical warning: In asthmatic patients treated with omalizumab, if persistent eosinophilia or new neurological symptoms occur, the possibility of EGPA should be highly vigilant and evaluated. Cite this article as: Wang Z, Lin S, Yang J, Cheng M, Cai M. Eosinophilic granulomatous polyangiitis emerging after omalizumab administration: an asthma patient without systemic corticosteroids develops mononeuritis multiplex after 22 days. Eur J Rheumatol. 2026, 13(1), 0048, doi: 10.5152/eurjrheum.2026.25048.</p>","PeriodicalId":12066,"journal":{"name":"European journal of rheumatology","volume":"13 1","pages":"1-5"},"PeriodicalIF":1.8,"publicationDate":"2026-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13051312/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147627323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pathogenic TET2 Variants and Autoinflammatory Manifestations in Myeloid Hematologic Malignancies: Case Report and Literature Review.","authors":"Óscar Porto Fuentes, Raquel De Paz Arias, Jorge Álvarez Troncoso","doi":"10.5152/eurjrheum.2026.24119","DOIUrl":"10.5152/eurjrheum.2026.24119","url":null,"abstract":"<p><p>Emerging evidence suggests that somatic mutations in genes associated with innate immunity can trigger adult-onset autoinflammatory diseases. Notably, loss-of-function variants in the TET2 gene have been linked to both hematological malignancies and immune-mediated disorders. A case is presented of a 73-year-old woman with chronic myelomonocytic leukemia who developed severe pericardial effusion secondary to inflammatory serositis, associated with a pathogenic TET2 variant. Despite initial treatment with corticosteroids and diuretics, her condition worsened, which led to the need to implement treatment with colchicine and anakinra. This regimen led to significant clinical improvement and resolution of the effusion. This case reflects the importance of searching for pathogenic variants in TET2 in patients with hematological disorders, with the aim of early recognition of inflammatory manifestations associated with this genetic alteration. Treatment with colchicine and anti-interleukin-1 should be considered in these cases, as they are effective and avoid the unnecessary use of other immunosuppressants. Cite this article as: Porto Fuentes Ó, de Paz Arias R, Álvarez Troncoso J. Pathogenic TET2 variants and autoinflammatory manifestations in myeloid hematologic malignancies: case report and literature review. Eur J Rheumatol. 2026, 13(1), 0119, doi:10.5152/eurjrheum.2026.24119.</p>","PeriodicalId":12066,"journal":{"name":"European journal of rheumatology","volume":"13 1","pages":"1-4"},"PeriodicalIF":1.8,"publicationDate":"2026-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13051314/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147627316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disease Course of Axial Spondyloarthritis in Pregnancy.","authors":"Sania Gore, Ritika Tambe, Asawari Raut, Pravin Patil","doi":"10.5152/eurjrheum.2026.24107","DOIUrl":"10.5152/eurjrheum.2026.24107","url":null,"abstract":"<p><strong>Objective: </strong>Limited information exists regarding the impact of axial spondyloarthritis (axSpA) on pregnancy compared to other chronic inflammatory disorders. Axial spondyloarthritis's unique anatomical and inflammatory impact on pregnancy presents challenges. This study aims to assess axSpA's progression during pregnancy.</p><p><strong>Methods: </strong>A retrospective observational study at a private rheumatology clinic assessed axSpA's progression during pregnancy in 80 women previously diagnosed with the condition.</p><p><strong>Results: </strong>Onset of axSpA occurred at an average age of 23.2 years. Symptoms worsened in 29 (36.25%) patients during pregnancy, while 51 (63.7%) experienced improvement or remission. Twelve (15%) women faced conception difficulties, with a delay of over a year. Cesarean sections were performed in 42 (62.6%) cases, while 25 (37.3%) had full-term vaginal deliveries.</p><p><strong>Conclusion: </strong>During pregnancy, there is a noticeable tendency for alterations in disease activity and symptoms experienced. This study highlights the need for better understanding and awareness of axSpA's impact on pregnancy outcomes. Cite this article as: Gore S, Tambe R, Raut A, Patil P. Disease course of axial spondyloarthritis in pregnancy. Eur J Rheumatol. 2026, 13, 0107, doi:10.5152/eurjrheum.2026.24107.</p>","PeriodicalId":12066,"journal":{"name":"European journal of rheumatology","volume":"13 1","pages":"1-3"},"PeriodicalIF":1.8,"publicationDate":"2026-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13051308/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147627346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Regression of a Refractory Pulmonary Lesion in Granulomatosis with Polyangiitis Following the Addition of Avacopan.","authors":"Daiki Nakagomi, Soichiro Kubota, Yoshiaki Kobayashi, Shunichiro Hanai","doi":"10.5152/eurjrheum.2026.25062","DOIUrl":"10.5152/eurjrheum.2026.25062","url":null,"abstract":"<p><p>Avacopan, a complement component 5a (C5a) receptor antagonist, is an emerging therapeutic agent for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis. However, its intrinsic efficacy remains unclear. A 74-year-old woman with granulomatosis with polyangiitis (GPA) presenting as a pulmonary mass, sinusitis, otitis media with hearing loss, and mononeuritis multiplex is reported. Initial remission was achieved with prednisolone and cyclophosphamide followed by maintenance with low-dose prednisolone and azathioprine. After 3 years, she relapsed with recurrent blood-stained sputum and enlargement of the pulmonary lesion despite negative ANCA titers. Infection and malignancy were excluded. Avacopan (60 mg/day) was introduced with low-dose prednisolone and azathioprine. Over 12 months, the pulmonary mass regressed, and blood-stained sputum improved, enabling complete withdrawal of prednisolone after 20 months. This case suggests a potential direct effect of avacopan on pulmonary inflammatory lesions in GPA and highlights the importance of long-term treatment evaluation. Cite this article as: Nakagomi D, Kubota S, Kobayashi Y, Hanai S. Regression of a refractory pulmonary lesion in granulomatosis with polyangiitis following the addition of avacopan. Eur J Rheumatol. 2026, 13, 0062, doi:10.5152/eurjrheum.2026.25062.</p>","PeriodicalId":12066,"journal":{"name":"European journal of rheumatology","volume":"13 1","pages":"1-3"},"PeriodicalIF":1.8,"publicationDate":"2026-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13051310/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147627373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rowell Syndrome with Lupus Podocytopathy: A Diagnostic Challenge.","authors":"Vinay Gera, Ahmed Waheed Kashif, Varghese Koshy, Binu Kunwar, Pankaj Das, Anuj Bhatnagar, Rahul Thombre, Nishu Bala, Lekshmi Priya Krishnan","doi":"10.5152/eurjrheum.2026.25007","DOIUrl":"10.5152/eurjrheum.2026.25007","url":null,"abstract":"<p><p>Rowell syndrome is a distinct subtype of systemic lupus erythematosus presenting with features of lupus as well as erythema multiforme. It has been well characterized by a different set of systemic signs and symptoms and a unique serological profile. Lupus podocytopathy (LP) is a rare pattern of lupus nephritis with a slightly different clinical and serological profile, natural course of the disease, as well as prognosis. A case of Rowell syndrome is presented, which was later diagnosed with LP on the basis of global effacement of podocytes on electron microscopy Cite this article as: Gera V, Kashif AW, Koshy V, et al. Rowell syndrome with lupus podocytopathy: A diagnostic challenge. Eur J Rheumatol. 2026, 13(1), 0007, doi:10.5152/eurjrheum.2026.25007.</p>","PeriodicalId":12066,"journal":{"name":"European journal of rheumatology","volume":"13 1","pages":"1-4"},"PeriodicalIF":1.8,"publicationDate":"2026-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13051309/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147627382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Profile of Patients with Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Single-Center Study.","authors":"Fatima K Alduraibi, James Haigney, Natalya Surmachevska, Dongmei Sun, John D Osborne, Maria I Danila","doi":"10.5152/eurjrheum.2025.24087","DOIUrl":"10.5152/eurjrheum.2025.24087","url":null,"abstract":"<p><p>Background: Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is a well-described complication of rheumatoid arthritis (RA). The authors sought to describe the characteristics, treatment strategies, and outcomes of RA-ILD patients at 6 and 12 months. Methods: Patients treated at the medical center between 2010 and 2019 with ICD9 and ICD10 codes for RA and interstitial lung disease (ILD) meeting American College of Rheumatology 1987 or 2010 ACR/European League Against Rheumatism classification criteria were considered for inclusion. The diagnosis of RA-ILD was based on clinical features, pulmonary function testing (PFT), and high-resolution computed tomography (HRCT) findings. Baseline demographics, body mass index , serologic status, tobacco use, PFT and HRCT findings, and RA-ILD treatments at 0, 6, and 12 months were extracted and analyzed. Results: Forty-seven patients diagnosed with RA-ILD were included in this analysis. The median age at diagnosis was 64.7 years, and the median duration of follow-up was 30 months. Thirty-two patients (68.09%) had follow-up data available at 6 months and 27 (57.45%) had follow-up data at 12 months. Twenty-three (48.9%) patients received treatment for RA-ILD. Forty-three (90.6%) and 42 (88.9%) patients exhibited stability/improvement of RA-ILD at 6 and 12 months of follow-up, respectively. Progression of RA-ILD at 6 months was associated with tobacco use (P=.025); however, no specific variable was associated with RA-ILD progression at 12 months. Conclusions: Patients with RA-ILD receiving treatment tend to show improvement or stability in lung disease at 6 and 12 months, although high attrition rate and short follow-up preclude finding of additional factors associated with ILD. Trial registration: Not applicable.</p>","PeriodicalId":12066,"journal":{"name":"European journal of rheumatology","volume":"12 3","pages":"1-7"},"PeriodicalIF":1.8,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12413663/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145032993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Experience of the Administration of First Dose IV Zoledronate at Queen Elizabeth Hospital.","authors":"Akshat Sinha, Brandon Karamveer Sangha","doi":"10.5152/eurjrheum.2025.24141","DOIUrl":"10.5152/eurjrheum.2025.24141","url":null,"abstract":"<p><p>Background: Osteoporosis affects nearly 3 million people in the UK, with bisphosphonates forming the mainstay of treatment. While the side effect profile of zoledronate is well-documented, adherence to prescribing guidance and specific population outcomes warrant further investigation. Our objectives were to assess whether zoledronate was prescribed correctly in accordance with guidance and evaluate the side-effect profile with attention to demographic variables. Methods: A retrospective analysis of 68 patients receiving their first dose of zoledronate at Queen Elizabeth Hospital, Birmingham (QEHB), between January and December 2021. Strict inclusion and exclusion criteria were applied. Patient records were reviewed for adherence to guidance, including pre-infusion checks and indication for treatment. Side effects were documented through postinfusion questionnaires. This timeframe was selected to capture a full year of prescribing patterns and ensure consistency in available data. Results: Among 68 patients (13 males, 55 females; age range 28-92), 96% were prescribed zoledronate for appropriate indications. Vitamin D was checked in 93%, and 100% underwent dual-energy X-ray absorptiometry (DXA) scans. However, only 16% had Fracture Risk Assessment Tool (FRAX) scores calculated. One patient received the infusion despite an estimated glomerular filtration rate < 35 mL/min. Side effects were reported in 37%, primarily bone/joint pain. Statistical analysis did not find a significant correlation between age, sex, or ethnicity and side-effect frequency (P > 0.05). Age appeared to influence post-dose symptoms, with older patients experiencing fewer side effects. Ocular symptoms were reported in 2 cases, and details of these were analyzed. South Asian females reported a higher incidence of side effects, but this observation remains exploratory due to the small sample size. Conclusion: This audit has shown that zoledronate is being prescribed in accordance with guidance at QEHB. Treatment is offered after systematic checks of biochemical parameters. However, the low rate of FRAX score calculation (16%) raises concerns about the completeness of fracture risk assessment. A potential explanation is the reliance on DXA scanning or clinical judgment, and a lack of transfer of information from primary care. Side effects reported are covered in patient information leaflets. Given that side effects were assessed 16 weeks post-infusion, recall bias should be considered a limitation. Further research is needed to ascertain predictors for subsequent adverse effects following infusion. Zoledronate prescription was largely in line with guidance, though notable gaps in fracture risk assessment were observed. The side effect profile aligned with existing literature, and demographic variations in adverse events should be interpreted cautiously given the sample size constraints.</p>","PeriodicalId":12066,"journal":{"name":"European journal of rheumatology","volume":"12 3","pages":"1-6"},"PeriodicalIF":1.8,"publicationDate":"2025-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12402432/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145032964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gingival Involvement in IgG4-Related Disease.","authors":"Sarah Al Qassimi, Rajaie Namas, Ahmed Alduaij, Anastasios Hantzakos, Mahdi Shkoukani","doi":"10.5152/eurjrheum.2025.25023","DOIUrl":"10.5152/eurjrheum.2025.25023","url":null,"abstract":"","PeriodicalId":12066,"journal":{"name":"European journal of rheumatology","volume":"12 3","pages":"1-2"},"PeriodicalIF":1.8,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12607665/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144947971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}